Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

NeoPharm and NCI expand collaboration for anticancer agent

March 6, 2001

NeoPharm's CRADA agreement for IL-13 receptor research extended

March 1, 2001

Positive quality-of-life and survival results reported for Maxim's Ceplene

March 1, 2001

FDA requests further information for Campath BLA

Feb. 23, 2001

Vical broadens clinical development of Allovectin-7

Feb. 22, 2001

Therion Biologics and the NCI move CEA-TRICOM cancer vaccine to phase I

Feb. 22, 2001

Phase II trials of SMART 1D10 antibody begin in non-Hodgkin's lymphoma

Feb. 21, 2001

Virulizin granted orphan drug status by FDA

Feb. 20, 2001

Distribution agreement for Pacis BCG terminated by UroCor and BioChem Pharma

Feb. 20, 2001

Melacine now available in Canada for treatment of stage IV melanoma

Feb. 16, 2001

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 28, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
News in brief
BioWorld Asia
BioWorld Asia briefs for April 28, 2026
Sichuan Kelun Pharmaceutical Research Institute discovers GPR6 inverse agonists
BioWorld Science
Sichuan Kelun Pharmaceutical Research Institute Co. Ltd. has identified G protein-coupled receptor 6 (GPR6) inverse agonists reported to be useful for the...
Grace Therapeutics hits CRL setback with GTx-104 despite positive trial
BioWorld
Grace Therapeutics Inc.’s hopes of becoming the first company in decades to update the standard of care in aneurysmal subarachnoid hemorrhage were delayed after...